IRIS International, Inc. Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	58
ISBN Number	not applicable
Product Code	GMD04747

Price

£490.00
approximately: $749 | €546

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a IRIS International, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook In Vitro Diagnostics
3 Business Description
- 3.1 Business Overview
- 3.2 Major Products and Services
  - 3.2.1 Overview
4 History
5 Competitors
6 Key Employees
7 Key Employee Biographies
8 Company Statement
9 Locations And Subsidiaries
- 9.1 Head Office
- 9.2 Other Locations & Subsidiaries
10 Recent Developments
- 10.1 Strategy And Business Planning
  - 10.1.1 May 22, 2007: IRIS International Announces Closing Of Its Subsidiary
- 10.2 Financial Announcements
  - 10.2.1 Jul 28, 2008: IRIS International Declares 2Q 2008 Results
  - 10.2.2 Apr 29, 2008: IRIS International Declares Q1 2008 Results
  - 10.2.3 Apr 14, 2008: IRIS International To Declare Q1 2008 Results
  - 10.2.4 Feb 26, 2008: IRIS International Declares Q4 2007 Results
  - 10.2.5 Nov 01, 2007: IRIS International Declares Q3 2007 Results
  - 10.2.6 Aug 13, 2007: IRIS International Declares Q2 2007 Results
  - 10.2.7 May 09, 2007: IRIS International Reports Q1 2007 Results
  - 10.2.8 Mar 07, 2007: IRIS International Reports Q4 And 2006 Results
  - 10.2.9 Nov 14, 2006: IRIS International Reports Q3 2006 Results
  - 10.2.10 Aug 02, 2006: IRIS International Reports Q2 2006 Results
  - 10.2.11 May 09, 2006: IRIS International Reports Q1 2006 Results
- 10.3 Corporate Communications
  - 10.3.1 Jul 31, 2008: IRIS International Elects New Board Member
  - 10.3.2 Nov 19, 2007: IRIS Elects Chairman
  - 10.3.3 Mar 05, 2007: IRIS International Appoints New President
  - 10.3.4 May 02, 2006: IRIS International Appoints New CFO
  - 10.3.5 May 02, 2006: IRIS International CFO Retires
  - 10.3.6 Apr 06, 2006: IRIS International Appoints New Director
- 10.4 Product News
  - 10.4.1 Apr 18, 2008: IRIS International Presents Study Results Of Its Investigational NADiA PSA Assay
  - 10.4.2 Apr 18, 2008: IRIS International, Inc. Achieves CE Mark For Its iChem VELOCITY Automated Urine Chemistry Analyzer
  - 10.4.3 Feb 26, 2008: IRIS International Announces Successful Completion Of Retrospective Study Using NADiA PSA Assay
  - 10.4.4 Dec 19, 2007: Iris Submits 510(K) Application To FDA For Its iCHEM Velocity Automated Urine Chemistry Analyzer
  - 10.4.5 Sep 17, 2007: Iris To Commence Shipping iCHEM VELOCITY Automated Urine Chemistry Analyzer In 1st Quater 2008
  - 10.4.6 Jul 13, 2007: Iris Expects Continued Strong Growth With Broadening Of Urinalysis Market And Development Of INew Products n Molecular Diagnostics And Hematology
  - 10.4.7 Feb 07, 2007: IRIS Submits 510(K) Application To FDA For Its N.A.D.I.A. Prostate Cancer Test
- 10.5 Product Approvals
  - 10.5.1 Apr 18, 2008: IRIS International, Inc. Achieves CE Mark For Its iChem VELOCITY Automated Urine Chemistry Analyzer
- 10.6 Clinical Trials
  - 10.6.1 Apr 18, 2008: IRIS International Presents Study Results Of Its Investigational NADiA PSA Assay
  - 10.6.2 Feb 26, 2008: IRIS International Announces Successful Completion Of Retrospective Study Using NADiA PSA Assay
11 IRIS International, Inc. Pipeline Products
- 11.1 IRIS International, Inc. Product Pipeline Analysis
  - 11.1.1 IRIS International, Inc. Pipeline Products By Equipment Type
  - 11.1.2 IRIS International, Inc. Pipeline Products By Development Stage
  - 11.1.3 IRIS International, Inc. Pipeline Products By Therapy Area
  - 11.1.4 IRIS International, Inc. Pipeline Products By Clinical Trials
  - 11.1.5 IRIS International, Inc. Pipeline Products By News Summary
- 11.2 iChem VELOCITY Automated Urine Chemistry Analyzer
  - 11.2.1 Product Description
  - 11.2.2 Product Status
  - 11.2.3 Product Milestone
- 11.3 NADIA - HIV
  - 11.3.1 Product Description
  - 11.3.2 Product Status
- 11.4 NADIA PSA
  - 11.4.1 Product Description
  - 11.4.2 Product Status
  - 11.4.3 Clinical Trials
  - 11.4.4 Product Milestone
- 11.5 Bubble Isolation-Bacteria
  - 11.5.1 Product Description
  - 11.5.2 Product Status
- 11.6 Circulating Epithelial Cells
  - 11.6.1 Product Description
  - 11.6.2 Product Status
- 11.7 Blood-based Her-2/neu Test
  - 11.7.1 Product Description
  - 11.7.2 Product Status
- 11.8 Prostate-Specific Antigen test
  - 11.8.1 Product Description
  - 11.8.2 Product Status
  - 11.8.3 Product Milestone
- 11.9 HIV Viral Load
  - 11.9.1 Product Description
  - 11.9.2 Product Status
- 11.10 NADIA Breast
  - 11.10.1 Product Description
  - 11.10.2 Product Status
- 11.11 Bacteriuria NP
  - 11.11.1 Product Description
  - 11.11.2 Product Status
- 11.12 NADIA CEC
  - 11.12.1 Product Description
  - 11.12.2 Product Status
- 11.13 3 GM Hematology
  - 11.13.1 Product Description
  - 11.13.2 Product Status
12 Appendix
- 12.1 Methodology
  - 12.1.1 Coverage
  - 12.1.2 Secondary Research
  - 12.1.3 Primary Research
  - 12.1.4 Expert Panel Validation
- 12.2 Contact Us
- 12.3 About Global Markets Direct
- 12.4 Disclaimer
1 List of Tables
- Table 1: IRIS International, Inc.,Key Facts
- Table 2: IRIS International, Inc., Key Employees,
- Table 3: IRIS International, Inc., Subsidiaries
- Table 4: IRIS International, Inc. Pipeline Products by Equipment Type
- Table 5: IRIS International, Inc. Pipeline Products By Development Stage
- Table 6: IRIS International, Inc. Pipeline Products By Therapy Area
- Table 7: IRIS International, Inc. Pipeline Products By Clinical Trials
- Table 8: IRIS International, Inc. Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: IRIS International, Inc. Pipeline Products By Equipment Type
- Figure 2: IRIS International, Inc. Pipeline Products By Equipment Type
- Figure 3: IRIS International, Inc. Pipeline Products By Development Stage
- Figure 4: IRIS International, Inc. Pipeline Products By News Summary
- Figure 5: Global Markets Direct Methodology